|
Press Releases |
|
|
|
Tuesday, March 22, 2022 |
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
Wednesday, March 16, 2022 |
|
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更 |
バイオジェン・インク(Nasdaq: BIIB、本社:米国マサチューセッツ州 ケンブリッジ、CEO:ミシェル・ヴォナッソス、以下 バイオジェン)とエーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、既存のアデュカヌマブ(米国の製品名ADUHELM)のコラボレーション契約を変更したことをお知らせします。 more info >> |
|
Tuesday, March 15, 2022 |
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
Friday, March 11, 2022 |
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
Wednesday, March 9, 2022 |
|
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) |
Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
Monday, March 7, 2022 |
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、自社創製のチロシンキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)の抗PD-1抗体「キイトルーダ(R)」(一般名:ペムブロリズマブ)との併用療法による治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得したことをお知らせします。 more info >> |
|
Friday, March 4, 2022 |
|
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク (Nasdaq: BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:ミシェル・ヴォナッソス、以下 バイオジェン)は、このたび、エーザイが、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブ(開発品コード:BAN2401)について、日本において医薬品事前評価相談制度に基づき、独立行政法人医薬品医療機器総合機構(PMDA)に申請データの提出を開始したことをお知らせします。 more info >> |
|
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Indonesian BFSI IT Summit: Revolutionizing Finance Through Digital Transformation
May 8, 2024 17:12 HKT/SGT
|
|
|
Crypto Oasis Thrives: UAE Blockchain Ecosystem sees Exponential Growth with 2,040 Active Organizations in Q1 2024
May 8, 2024 17:00 HKT/SGT
|
|
|
Datacloud APAC: Charting the Course for APAC's Cloud Future
May 8, 2024 16:20 HKT/SGT
|
|
|
アフリカがついに日本のビジネスにおける国境を開放
May 8, 2024 15:00: JST
|
|
|
以数智化殡葬直面变化与挑战 福寿园国际集团组团参加2024AFE亚洲殡仪及墓园博览暨会议
May 8, 2024 14:05 HKT/SGT
|
|
|
以數智化殯葬直面變化與挑戰 福壽園國際集團組團參加2024AFE亞洲殯儀及墓園博覽暨會議
May 8, 2024 14:01 HKT/SGT
|
|
|
Mitsubishi Heavy Industries Increases Dividends on Back of Historically High FY2023 Results, Releases FY2024 Guidance
May 8, 2024 14:27 JST
|
|
|
Capital.com's Client Trading Volumes Surpass USD1 trillion in 2023
May 8, 2024 13:00: JST
|
|
|
Capital.com 的客戶交易量在2023年超過了1萬億美元
May 8, 2024 12:18 HKT/SGT
|
|
|
Capital.com的客户交易量在2023年超过了1万亿美元
May 8, 2024 12:12 HKT/SGT
|
|
|
Capital.com's Client Trading Volumes Surpass USD1 trillion in 2023
May 8, 2024 12:00 HKT/SGT
|
|
|
Spritzer EcoPark Taiping Brightens up the Sky with an Enchanting Aurora Light Show at Food, Arts and Music Carnival
May 8, 2024 11:32 HKT/SGT
|
|
|
Rome becomes the first European city to offer open loop transit payments to JCB Cardmembers
May 8, 2024 12:00 JST
|
|
|
点燃新质生产力“火花” 诺奖得主英雄论道中新广州知识城
May 8, 2024 10:50 HKT/SGT
|
|
|
點燃新質生產力“火花” 諾獎得主英雄論道中新廣州知識城
May 8, 2024 10:41 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|